The Affordability Race is On
Affordability has shifted from industry challenge to industry mandate. As pressure mounts from policymakers, employers and patients, manufacturers are moving quickly to respond. But in the race to lower costs and improve access, many are adopting highly visible solutions without fully considering whether they are the right fit.
At Asembia’s AXS26 Summit, HealthDyne leaders will take the stage to challenge that momentum. The session will examine how direct-to-patient and other consumer-first models are reshaping the pharmacy landscape while addressing one of the most pressing questions facing pharmaceutical manufacturers today: Which access models will truly endure?
The Affordability Race: Which Models Will Endure?
Presenters: David Skomo, RPh, Chief Operating Officer, and Sarah Thomas, SVP, Head of Growth & Commercialization
Location: Asembia AXS26 Summit, Las Vegas
Date: Wednesday, April 29 11:00 am PT
While direct-to-patient models may feel like new innovations, their roots stretch back decades, from fertility treatments in the 1990s to the digital expansion of lifestyle medications in the 2000s. What’s changed is the urgency. Mounting affordability pressures, increased regulatory scrutiny and rising consumer expectations are raising the stakes.
“Affordability has become the defining issue for our industry, but there’s a real risk in how companies respond,” said David Skomo, Chief Operating Officer at HealthDyne. “We’re seeing a push toward direct-to-patient models, but without a clear framework, those strategies can fall short of improving access and affordability in a meaningful way.”
“Too many affordability strategies are still built around legacy channels instead of reimagining access,” said Sarah Thomas, SVP, Head of Growth & Commercialization at HealthDyne. “The next wave of leaders won’t just adjust pricing. They’ll fundamentally redesign how therapies reach patients. That’s where real affordability gains will come from.”
As affordability pressures continue to evolve, success will depend on more than speed. The manufacturers that win will be those who take a strategic, patient-centric approach and match the right model to the right therapy. Join David and Sarah at Asembia to explore how to choose the path that will endure.
